Photodynamic applications in superficial bladder cancer: Facts and hopes!

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 25, Issue 1-2, 2006, Pages 441-451

  Jichlinski, Patrice ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Aminolevulinic acid; Bladder cancer; Carcinoma in situ; Fluorescence cystoscopy; Hematoporphyrin derivatives; Hexaminolevulinate; Hypericin; Photodiagnosis; Photodynamic therapy; Transitional cell carcinoma

Indexed keywords

AMINOLEVULINIC ACID; BCG VACCINE; DIHEMATOPORPHYRIN ESTER; HEMATOPORPHYRIN; HEXAMINOLEVULINATE; HYPERICIN; PHOTOFRIN; PHOTOFRIN II; PHOTOSENSITIZING AGENT; THIOTEPA; UNCLASSIFIED DRUG;

BLADDER CANCER; BLADDER TUMOR; BLADDER WALL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; COMPARATIVE STUDY; CYSTOSCOPY; DIAGNOSTIC PROCEDURE; DRUG HALF LIFE; DRUG UPTAKE; ENDOSCOPY; FLUORESCENCE; HEALTH SURVEY; HUMAN; HYPERICUM PERFORATUM; HYPOTENSION; ILLUMINATION; IMMUNOTHERAPY; LASER; MEDICAL RESEARCH; NONHUMAN; PHOTOACTIVATION; PHOTOCHEMISTRY; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; REVIEW; SAFETY;

HYPERICUM PERFORATUM;

EID: 33644759516     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.280     Document Type: Review

References (38)

1. Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol 2003; 15:227-233.
2. Kurt KH, Bouffioux C, Sylvester R, van den Meijden APM, Oosterlinck W, Brausi M, the EORTC Genitourinary Group. Treatment of superficial bladder tumors: achievement and needs. Eur Urol 2000; 37(Suppl 3):1-9.
3. Kriegmair M, Baumgartner R, Hofstetter A. Intravesikale Instillation von Delta-Aminolävulinsäure (ALA)-Eine neue Methode zur photodynamischen Diagnostik und Therapie. Lasermedizin 1992; 8S:83.
4. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, Hofstadter F, Hofstetter A. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994; 44:836-841.
5. Jichlinski P, Forrer M, Mizeret J, Glanzmann T, Braichotte D, Wagnières G, Zimmer G, Guillou L, Schmidlin F, Graber P, van den Bergh H, Leisinger HJ. Clinical evaluation of a method for detecting superficial transitional cell carcinoma of the bladder by light induced fluorescence of protoporphyrin IX following topical application of 5-aminolevulinic acid. Preliminary results. Lasers Surg Med 1997; 20:402-408.
6. Koenig F, McGovern FJ, Lame R, Enquist H, Schomacker KT, Deutsch TF. Diagnosis of bladder carcinoma using protoporphyrin FX fluorescence induced by 5-aminolaevulinic acid. BJU Int 1999; 83:129-135.
7. Zaak D, Kriegmair M, Stepp H, Stepp H, Baumgartner R, Oberneder R, Schneede P, Corvin S, Frimberger D, Knuchel R, Hofstetter A. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 2001; 57:690-694.
8. Lange N, Jichlinski P, Zellweger M, Forrer M, Marti A, Guillou L, Kucera P, Wagnières G, van den Bergh H. Photodetection of early human bladder cancer based on the fluorescemce of 5-aminolevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 1999; 80:185-193.
9. Jichlinski P, Guillou L, Karlsen SJ, Malmstrom PU, Jocham D, Brennhovd B, Johansson E, Gartner T, Lange N, van den Bergh H, Leisinger HJ. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 2003; 170:226-229.
10. D'Hallewin MA, De Witte P, Waelkens E, Merlevede W, Baert L. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J Urol 2000; 164:349-351.
11. D'Hallewin MA, Kamuhabwa AR, Roskams T, de Witte PA, Baert L. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU 2002; 89:760-763.
12. Krieg RC, Fickweiler S, Wolfbeis OS, Knuechel R. Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro. Photochem Photobiol 2000; 72:226-233.
13. D'Hallewin MA, Bezdetnaya L, Guillemin F. Fluorescence detection of bladder cancer: a review. Eur Urol 2002; 42:417-425.
14. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M, Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171:135-138.
15. Gomella LG, Grossman HB, Presti JC, Lerner SP, Cookson MS, Albala DM, Nseyo UO, Fradet Y, Bihrle R, Fuchs GJ, Morales A, Chad WMR, Droller MJ. The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of carcinoma in situ of the urinary bladder. J Urol 2004; 171:264A
16. Kriegmair M, Zaak D, Rothenberger KH, Rassweiler J, Jocham D, Eisenberger F, Tauber R, Stenzl A, Hofstetter A. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002; 168:475-478.
17. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002; 168:67-71.
18. Grossman HB, Gomella LG, Fradet Y, Presti JC, Chad WMR, Lerner SP, Cookson MS, Nseyo UO, Bihrle R, Fuchs GJ, Schoenberg MP, Droller MJ. The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of stage TA/T1 urothelial cancer in the urinary bladder. J Urol 2004; 171:263A.
19. Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. 5-aminolevulinic acid induced fluorescence endoscopy applied after conventional resection of primary superficial bladder tumors. Urology 1999; 53:77-81.
20. Durek C, Wagner S, Zeylemaker B, Van Moorselaar J, Witjes F, Grimm MO, Muschter R, Popken G, König F, Kurth KH, Knüchel-Clarke R, Jocham D. The significance of Hexyl 5-aminolevulinate hydrochloride based fluorescence cystoscopy in treatment decisions-results of a prospective phase 3 multicenter study. Eur Urol 2004; 3:369A.
21. Gudgin Dickson EF, Goyan RL, Pottier RH. New directions in photodynamic therapy. Cell Mol Biol 2002; 48:939-954.
22. Moor ACE. Signaling pathways in cell death and survival after photodynamic therapy. Photochem Photobiol B 2000; 57:1-13.
23. Kelly JF, Snell ME. Hematoporphyrin derivative. A possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol 1976; 115:150-151.
24. Walther Mc M. The role of photodynamic therapy in the treatment of recurrent superficial bladder cancer. Urol Clin North Am 2000; 27:163-170.
25. Jichlinski P, Leisinger HJ. Photodynamic therapy in superficial bladder cancer: past,present and future. Urol Res 2001; 29:396-405.
26. van Staveren HJ, Bertrams RH, Star WM. Bladder PDT with intravesical clear and light scattering media: effect of an eccentric isotropic light source on light distribution. Lasers Surg Med 1997; 20:248-253.
27. Beyer W. Systems for light application and dosimetry in photodynamic therapy. Photochem Photobiol B 1996; 36:153-156.
28. Cosserat-Gerardin (First initial?), Bezdetnaya L, Notter D, Vigneron C, Guillemin F. Biosynthesis and photodynamic efficacy of protoporphyrin IX (PpIX) generated by 5-aminolevulinic acid (ALA) or its hexylester (hALA) in rat bladder carcinoma cells. Photochem Photobiol B2000; 59:72-79.
29. Grönlund-Pakkanen S, Wahlfors J, Talja M, Kosma VM, Pakkanen TM, ALA-Opass M, Alhava E, Moore RB. The effect of photodynamic therapy on rat urinary bladder with orthotopic urothelial carcinoma. BJU 2003; 92:125-130.
30. Xiao Z, Brown K, Tulip J, Moore RB. Whole bladder photodynamic therapy for orthotopic superficial bladder cancer in rats: a study of intravenous and intravesical administration of photosensitizers. J Urol 2003; 169:352-356.
31. Kriegmair M, Baumgartner R, Lumper W, Waidelich R, Hofstetter A. Early clinical experience with 5-aminolevulinic acid for photodynamic therapy of superficial bladder cancer. BJU 1997; 77:667-671.
32. D'Hallewin MA, Star W, Baert L. Initial evaluation of whole bladder wall photodynamic therapy after intravesical ALA sensitization for carcinoma in situ of the bladder. SPIE 1997; 3191:210-213.
33. Waidelich R, Hofstetter A, Stepp H, Baumgartner R, Weninger E, Kriegmair M. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumors. J Urol 1998; 159:401-404.
34. Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001; 165:1904-1907.
35. Shackley DC, Briggs C, Gilhooley A, Whitehurst C, O'Flynn KJ, Betts CD, Moore JV, Clarke NW. Photodynamic therapy for superficial bladder cancer under local anaesthetic. BJU 2002; 89:665-670.
36. Waidelich R, Beyer W, Knüchel R, Stepp H, Baumgartner R, Schröder J, Hofstetter A, Kriegmair M. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology 2003; 61:332-337.
37. Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single center study. Urology 2003; 61:338-341.
38. Berg K, Selbo PK, Prasmickaite L, Tjelle TE, Sandvig K, Moan J, Gaudernack G, Fodstad O, Kjolsrud S, Anholt H, Rodal GH, Rodal SK, Hogset A. Photochemical internalization: a novel technology for delivery of macromolecules in cytosol. Cancer Res 1999; 59:1180-1183.